ME02529B - Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze - Google Patents
Fuzionisana triciklična j edinjenja kao inhibitori raf kinazeInfo
- Publication number
- ME02529B ME02529B MEP-2016-172A MEP17216A ME02529B ME 02529 B ME02529 B ME 02529B ME P17216 A MEP17216 A ME P17216A ME 02529 B ME02529 B ME 02529B
- Authority
- ME
- Montenegro
- Prior art keywords
- heterocyclyl
- alkyl
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 102000009929 raf Kinases Human genes 0.000 title claims 3
- 108010077182 raf Kinases Proteins 0.000 title claims 3
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 25
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000001188 haloalkyl group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 101150020251 NR13 gene Proteins 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 alkinil Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001952 enzyme assay Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
| EP11879096.3A EP2797888B1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02529B true ME02529B (me) | 2017-02-20 |
Family
ID=48696279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-172A ME02529B (me) | 2011-12-31 | 2011-12-31 | Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9273046B2 (en:Method) |
| EP (2) | EP3124472B1 (en:Method) |
| JP (1) | JP5868521B2 (en:Method) |
| KR (1) | KR101713391B1 (en:Method) |
| CN (1) | CN103596926B (en:Method) |
| AU (1) | AU2011384857B2 (en:Method) |
| BR (1) | BR112014013108B1 (en:Method) |
| CA (1) | CA2856347C (en:Method) |
| CY (1) | CY1118226T1 (en:Method) |
| DK (1) | DK2797888T3 (en:Method) |
| EA (1) | EA025597B1 (en:Method) |
| ES (1) | ES2588775T3 (en:Method) |
| HR (1) | HRP20160641T1 (en:Method) |
| HU (1) | HUE029656T2 (en:Method) |
| IL (1) | IL233364A (en:Method) |
| IN (1) | IN2014DN06166A (en:Method) |
| LT (1) | LT2797888T (en:Method) |
| ME (1) | ME02529B (en:Method) |
| MX (1) | MX352617B (en:Method) |
| NZ (1) | NZ624068A (en:Method) |
| PL (1) | PL2797888T3 (en:Method) |
| PT (1) | PT2797888T (en:Method) |
| RS (1) | RS55196B1 (en:Method) |
| SG (1) | SG11201401725SA (en:Method) |
| SI (1) | SI2797888T1 (en:Method) |
| SM (1) | SMT201600302B (en:Method) |
| WO (1) | WO2013097224A1 (en:Method) |
| ZA (1) | ZA201405555B (en:Method) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401725SA (en) | 2011-12-31 | 2014-09-26 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
| EA029412B1 (ru) | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| GB201416186D0 (en) | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| MX381053B (es) * | 2015-04-15 | 2025-03-12 | Beigene Ltd | Formas cristalinas de las sales del compuesto 5-(((1r,1as,6br)-1-(6-(trifluorometil)-1h-benzo[d]imidazol-2-il)-1a,6b-dihidro-1h-ciclopropa [b] benzofuran-5-il) oxi)-3,4-dihidro-1,8-naftiridin-2(1h)-ona, sus métodos de preparación sus usos de las mismas. |
| JP6175519B2 (ja) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| CA3042968C (en) | 2016-12-01 | 2023-10-17 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| AU2017382436C1 (en) * | 2016-12-23 | 2021-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| CA3152401A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US11883393B2 (en) | 2019-12-19 | 2024-01-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| IL300113A (en) | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Compressed cyclic RAF inhibitors and methods of using them |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| IL301155A (en) | 2020-09-14 | 2023-05-01 | Arvinas Operations Inc | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| AU2021412688B2 (en) * | 2020-12-29 | 2025-06-12 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| US20240368109A1 (en) * | 2021-09-21 | 2024-11-07 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
| WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
| WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068773A1 (en) | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
| CA2590294A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| CA2589779A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
| MX2007014510A (es) | 2005-05-20 | 2008-02-05 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos de uso de los mismos. |
| BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
| CA2620864A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| US8110687B2 (en) * | 2005-12-08 | 2012-02-07 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| ATE552245T1 (de) * | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| AU2007287319A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as GSK-3 inhibitors |
| US8067599B2 (en) | 2006-09-06 | 2011-11-29 | Hoffman-La Roche Inc. | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors |
| US20080064729A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| EA016329B1 (ru) * | 2007-05-04 | 2012-04-30 | Айрм Ллк | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR |
| CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| SG11201401725SA (en) | 2011-12-31 | 2014-09-26 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
| MX381053B (es) | 2015-04-15 | 2025-03-12 | Beigene Ltd | Formas cristalinas de las sales del compuesto 5-(((1r,1as,6br)-1-(6-(trifluorometil)-1h-benzo[d]imidazol-2-il)-1a,6b-dihidro-1h-ciclopropa [b] benzofuran-5-il) oxi)-3,4-dihidro-1,8-naftiridin-2(1h)-ona, sus métodos de preparación sus usos de las mismas. |
-
2011
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/pl unknown
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/ko active Active
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/lt unknown
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/pt active IP Right Grant
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
- 2011-12-31 SI SI201130852A patent/SI2797888T1/sl unknown
- 2011-12-31 PT PT118790963T patent/PT2797888T/pt unknown
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/es active Active
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 HR HRP20160641TT patent/HRP20160641T1/hr unknown
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/me unknown
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/zh active Active
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 RS RS20160713A patent/RS55196B1/sr unknown
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/ja active Active
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 MX MX2014007829A patent/MX352617B/es active IP Right Grant
- 2011-12-31 EA EA201491305A patent/EA025597B1/ru not_active IP Right Cessation
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en active Application Filing
-
2014
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/el unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/it unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02529B (me) | Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze | |
| ME02855B (me) | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI | |
| HRP20240300T1 (hr) | Spoj [1,2,4]triazolo[1,5-a]piridina kao inhibitor jak i njegova primjena | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| NL2000373C2 (nl) | Antibacteriële middelen. | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| HRP20150184T1 (hr) | Makrocikliäśki spoj i postupci za njegovu proizvodnju | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| ME00876B (me) | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati | |
| HRP20130942T1 (hr) | Aminodiazepini kao modulatori toll-u sliäśnih receptora | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| JP2012528194A (ja) | Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物 | |
| AU2023241329A1 (en) | Psychotropic agents and uses thereof | |
| HRP20191525T1 (hr) | Inhibitori replikacije virusa influence | |
| RU2008141239A (ru) | Соединения тетрагидропиридотиенопиримидина и способы их применения | |
| JP2016513108A5 (ja) | 治療用化合物 | |
| JP2016512225A (ja) | アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体 | |
| EA200970455A1 (ru) | ЗАМЕЩЕННЫЙ 8-ПИПЕРИДИНИЛ-2-ПИРИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОН И ПРОИЗВОДНЫЕ 8-ПИПЕРИДИНИЛ-2-ПИРИМИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| HRP20140409T1 (hr) | Derivat imidazola sa strukturom prolinskog prstena |